Form 8-K ALNYLAM PHARMACEUTICALS, For: Aug 01
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Wall St rises as oil slide offers respite after Fed rate hike
- Oil falls 2% to one-week low as Middle East supply disruption fears ease
- The Fed is hiking. Why isn't UBS worried about stocks?
- Wall Street on Fed rate hike: 'As hawkish as it gets'
- RBC bullish on Kraft Heinz, sees return to growth in 2027
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
- GlobalFoundries and Marvell expand SiGe capacity for optical networking
Alnylam Pharmaceuticals (ALNY) PT Raised to $300 at RBC Capital
August 2, 2024 6:21 AM EDTRBC Capital analyst Luca Issi raised the price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $300.00 (from $265.00) while maintaining a Outperform rating.
The analyst comments "Strong beat and raise with $410m product revenue ahead of consensus ($367m) and guide raised 11% at the... More
